BioAge 10-Q: Q3 Net Loss Widens to $33.5M as BGE-102 Costs Climb; $352.3M Cash Funds Runway Through 2029
BIOA is trading near its 52-week low of $4.81 (14% above the low).
Summary
BioAge's Q3 2026 10-Q shows a $33.5 million net loss on $30.2 million of R&D, offset by $352.3 million in cash that funds operations through 2029. QUELL-CV topline data is expected in Q4 2026.
Key Events · Earnings and Guidance · BIOA
-
Q3 Loss Widens on Trial Spend
Net loss of $33.5 million, or $0.73 per share, versus $20.2 million ($0.56) a year earlier; nine-month net loss was $81.9 million versus $54.7 million.
-
BGE-102 Costs Drive R&D Jump
Research and development rose to $30.2 million from $18.5 million, with BGE-102 direct program costs up $13.2 million on QUELL-CV and QUELL-DME trial and manufacturing costs.
-
Cash Funds Runway Through 2029
$352.3 million in cash, cash equivalents and marketable securities as of September 30, 2026, of which $68.7 million was long-term; accumulated deficit reached $415.3 million.
-
QUELL-CV Topline Due Q4 2026
The Phase 2 dose-ranging obesity/inflammation trial completed enrollment of approximately 160 participants, with topline expected in the fourth quarter of 2026; QUELL-DME topline is expected in the second half of 2027.
Analysis · BIOA · Life Sciences
The quarterly loss widened sharply to $33.5 million from $20.2 million a year earlier, driven by research spending on the lead NLRP3 program BGE-102, which jumped to $30.2 million from $18.5 million as the QUELL-CV and QUELL-DME trials ramp. That burn is covered: $352.3 million in cash and securities at September 30, 2026 funds operations through 2029, so there is no near-term financing pressure. The next hard data point is QUELL-CV topline in Q4 2026, which will determine whether the spending is producing a viable drug.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIOA was trading at $5.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $254.3M. The 52-week trading range was $4.81 to $25.96. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.